- Réseau des ambassadeurs
- Jeunes Ambassadeurs d'Alsace
- Vie du Club
- Vos outils
Vous êtes ici
Transgene and Jennerex Announce First Patient Treated in Phase 1/2 Clinical Trial of JX594/TG6006 in Combination with C...
21 mars 2012
San Francisco, California and Strasbourg, France - Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX594 in patients with whose metastatic colorectal cancer has become refractory to...
Retrouvez tout l'article Transgene and Jennerex Announce First Patient Treated in Phase 1/2 Clinical Trial of JX594/TG6006 in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer sur le site BioValley.com - Latest News.
Droits d'auteur © 2012. Tous droits réservés. BioValley the Trinational Network